Rebbeca Irene Spain

Rebbeca Irene Spain

Auto-generated profile, based on publicly available information

Rebbeca Irene Spain

Department of Neurology, Oregon Health & Science University, Portland, OR, USA; Portland VA Medical Center, Portland, OR, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of NeuroEngineering and Rehabilitation
Verified
Journal Article
Open access
PDF file
VSVrutangkumar V Shah
Vrutangkumar V Shah
James McNamesJames McNames
James McNames
Martina ManciniMartina Mancini
Martina Mancini
Patricia (Patty) Carlson-KuhtaPatricia (Patty) Carlson-Kuhta
Patricia (Patty) Carlson-Kuhta
RSRebecca I. Spain
Rebecca I. Spain
FHFay Horak
Fay Horak
Background and purpose: Recent findings suggest that a gait assessment at a discrete moment in a clinic or laboratory setting may not reflect functional, everyday mobility. As a step towards better understanding gait during daily life in neurological populations, we compared gait measures that best discriminated people with multiple sclerosis (MS) and people with Parkinson’s Disease (PD) from their respective, age-matched, healthy control subjects (MS-Ctl, PD-Ctl) in laboratory tests versus a week of daily life monitoring. Methods: We recruited 15 people with MS (age mean ± SD: 49 ± 10 years), 16 MS-Ctl (45 ± 11 years), 16 people with idiopathic PD (71 ± 5 years), and 15 PD-Ctl (69 ± 7 years). Subjects wore 3 inertial sensors (one each foot and lower back) in the laboratory followed by 7 days during daily life. Mann–Whitney U test and area under the curve (AUC) compared differences between PD and PD-Ctl, and between MS and MS-Ctl in the laboratory and in daily life. Results: Participants wore sensors for 60–68 h in daily life. Measures that best discriminated gait characteristics in people with MS and PD from their respective control groups were different between the laboratory gait test and a week of daily life. Specifically, the toe-off angle best discriminated MS versus MS-Ctl in the laboratory (AUC [95% CI] = 0.80 [0.63–0.96]) whereas gait speed in daily life (AUC = 0.84 [0.69–1.00]). In contrast, the lumbar coronal range of motion best discriminated PD versus PD-Ctl in the laboratory (AUC = 0.78 [0.59–0.96]) whereas foot-strike angle in daily life (AUC = 0.84 [0.70–0.98]). AUCs were larger in daily life compared to the laboratory. Conclusions: Larger AUC for daily life gait measures compared to the laboratory gait measures suggest that daily life monitoring may be more sensitive to impairments from neurological disease, but each neurological disease may require different gait outcome measures.

1 September 2017 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
FBFrank Bittner
Frank Bittner
CMCharles Murchison
Charles Murchison
DKDennis Koop
Dennis Koop
DBDennis Bourdette
Dennis Bourdette
RSRebecca Spain
Rebecca Spain

25 March 2020 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MCMichelle Cameron
Michelle Cameron
CTCassidy Taylor
Cassidy Taylor
JLJodi Lapidus
Jodi Lapidus
KRKatrina Ramsey
Katrina Ramsey
DKDennis Koop
Dennis Koop
RSRebecca Spain
Rebecca Spain

6 August 2021 in Journal of Neuroimaging
Verified
Journal Article
Open access
PDF file
ITIan J Tagge
Ian J Tagge
VAValerie C Anderson
Valerie C Anderson
CSCharles S Springer
Charles S Springer
MSManoj K Sammi
Manoj K Sammi
DBDennis N Bourdette
Dennis N Bourdette
WRWilliam D Rooney
William D Rooney
Background and Purpose: To compare transcapillary wall water exchange, a putative marker of cerebral metabolic health, in brain T2 white matter (WM) lesions and normal appearing white and gray matter (NAWM and NAGM, respectively) in individuals with progressive multiple sclerosis (PMS) and healthy controls (HC).Methods: Dynamic‐contrast‐enhanced 7T MRI data were obtained from 19 HC and 23 PMS participants. High‐resolution pharmacokinetic parametric maps representing tissue microvascular and microstructural properties were created by shutter‐speed (SS) paradigm modeling to obtain estimates of blood volume fraction (vb), water molecule capillary efflux rate constant (kpo), and the water capillary wall permeability surface area product (PwS ≡ vb*kpo). Linear regression models were used to investigate differences in (i) kpo and PwS between groups in NAWM and NAGM, and (ii) between WM lesions and NAWM in PMS.Results: High‐resolution parametric maps were produced to visualize tissue classes and resolve individual WM lesions. Normal‐appearing gray matter kpo and PwS were significantly decreased in PMS compared to HC (p ≤ .01). Twenty‐one T2 WM lesions were analyzed in 10 participants with PMS. kpo was significantly decreased in WM lesions compared to PMS NAWM (p < .0001).Conclusions: Transcapillary water exchange is reduced in PMS NAGM compared to HC and is further reduced in PMS WM lesions, suggesting pathologically impaired brain metabolism. kpo provides a sensitive measure of cerebral metabolic activity and/or coupling, and can be mapped at higher spatial resolution than conventional imaging techniques assessing metabolic activity.

13 January 2026 in Neurology
Verified
Journal Article
Closed access
RSRebecca I. Spain
Rebecca I. Spain
MSM. Mateo Paz Soldán
M. Mateo Paz Soldán
MFMark S. Freedman
Mark S. Freedman
PRPavle Repovic
Pavle Repovic
ASAndrew J. Solomon
Andrew J. Solomon
WRWilliam Rooney
William Rooney
A pilot trial of the antioxidant lipoic acid (LA) in secondary progressive multiple sclerosis (MS) demonstrated a reduction in the whole-brain atrophy, suggesting neuroprotection. This study determined whether LA preserved walking speed, reduced brain atrophy, and was safe in progressive MS (PMS). This phase 2, 24-month, randomized, double-blind, placebo-controlled clinical trial (2018-2023) recruited a convenience sample from 10 US sites, including 5 Veterans Affairs medical centers and 1 Canadian site. Inclusion criteria were as follows: age ≥18 years, primary or secondary PMS, Expanded Disability Status Scale (EDSS) score 3.0-6.5, and relapse-independent disability worsening in the previous 2 years. Exclusion criteria were as follows: confounders of mobility outcomes, LA use in the previous 2 years, and MRI contraindications. Concurrent disease-modifying therapy (DMT) was permitted. Participants were block-randomized by site (1:1) to receive 1,200 mg daily oral LA or placebo. The sample size (n = 118) was powered to detect Timed 25-Foot Walk (primary outcome) speed differences, allowing 25% attrition. Secondary outcomes were brain atrophy, other clinical and patient-reported disabilities, and adverse events. Study visits occurred every 6 months. Laboratory monitoring was increased to every 3 months because of treatment-related proteinuria. Intention-to-treat analysis used linear mixed-effects models. Participants in the LA (54) and placebo (61) groups were 54.8% female (age 59.1 (SD 8.5) years), with a disease duration of 16.3 (SD 9.7) years and a median EDSS score of 6.0 (interquartile range 4.0-6.0), and 55.7% were on DMT. Groups were matched at baseline. LA participants discontinued from the study more often (37%) than placebo (17%). LA did not slow declines in walking speed (-0.39 ft/sec vs -0.30 ft/sec; -0.08 [-0.33 to 0.17]), nor showed differences in mobility, other clinical, or patient-reported outcomes from placebo. Whole-brain volume seemed stable in LA participants, whereas it trended toward a decrease in placebo, even after accounting for an increased total T2-weighted lesion volume that was greater in the LA group. Deep gray matter volume remained stable in LA participants and decreased in placebo participants. The LA group experienced more proteinuria and fewer suicidal ideation events than the placebo group. LA did not slow decline in walking speed or have other clinical effects different from placebo and was associated with newly described adverse events. Investigating LA mechanisms may help interpretation of volumetric imaging biomarkers in PMS. NCT03161028. clinicaltrials.gov/study//NCT03161028, first submission May 18, 2017; first patient enrolled August 17, 2018. This study provides Class II evidence that in people with primary or secondary PMS, oral LA did not improve timed walking speed at 24 months compared with placebo.

26 April 2026 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
CHChris Hollen
Chris Hollen
CGCarolina Garcia
Carolina Garcia
CHChristopher C Hemond
Christopher C Hemond
RSRebecca I Spain
Rebecca I Spain
CCCole Crowson
Cole Crowson
ESElizabeth Silbermann
Elizabeth Silbermann
Background: Paramagnetic rim lesions (PRLs) detected on susceptibility-sensitive magnetic resonance imaging (MRI) represent chronic active lesions and correlate with disease progression in multiple sclerosis (MS). However, optimal detection methods remain unclear. Objective: To compare PRL detection using filtered-phase imaging versus susceptibility-weighted imaging (SWI) and assess inter-rater reliability among clinical neuroimmunologists. Methods: We retrospectively analyzed 3T MRI from 44 relapsing-remitting MS patients. Four neurologists with neuroimmunology training received 30-minute training sessions and evaluated PRLs on both filtered-phase and SWI sequences. Consensus adjudication resolved discordant ratings and served as the reference standard for calculating diagnostic accuracy. Results: PRLs were identified in 21/44 patients (48%). Relative to consensus as the reference standard, SWI demonstrated higher sensitivity than filtered-phase imaging (66.0% vs. 60.4%), while filtered phase showed superior positive predictive value (0.903 vs. 0.714). Both sequences achieved very high specificity (>97%). Inter-rater reliability was good for SWI (Intraclass Correlation Coefficient [ICC] = 0.85) and moderate for filtered phase (ICC = 0.71) for per-subject PRL counts. Vascular complexity was the most common cause of false-positive identification (65% of cases). Conclusions: Both techniques reliably detect PRLs with substantial inter-rater agreement. Filtered-phase imaging offers superior positive predictive value, while SWI provides better sensitivity and inter-rater reliability. Further development of a standardized training program for assessment of PRL and studies directly comparing susceptibility-sensitive sequences on different vendor platforms are warranted.